Ayvakit™ (avapritinib) – New orphan drug approval
January 9, 2020 - The FDA announced the approval of Blueprint Medicines’ Ayvakit (avapritinib), for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
Top